Zuclopenthixol dihydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526500

CAS#: 58045-23-1 (HCl)

Description: Zuclopenthixol, also known as Cisordinol, Clopixol, Acuphase, zuclopentixol, is a typical antipsychotic drug of the thioxanthene class. It was introduced in 1962 by Lundbeck. Zuclopenthixol is the cis-isomer of clopenthixol. Zuclopenthixol is not approved for use in the United States. Zuclopenthixol has high affinity for both dopamine D1 and D2 receptors, for α1-adrenoceptors and 5-HT2 receptors but no affinity for cholinergic muscarine receptors. It has weak histamine (H1) receptor affinity and no α2-adrenoceptor blocking activity.

Chemical Structure

Zuclopenthixol dihydrochloride
CAS# 58045-23-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 526500
Name: Zuclopenthixol dihydrochloride
CAS#: 58045-23-1 (HCl)
Chemical Formula: C22H27Cl3N2OS
Exact Mass: 472.09
Molecular Weight: 473.880
Elemental Analysis: C, 55.76; H, 5.74; Cl, 22.44; N, 5.91; O, 3.38; S, 6.77

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 53772-83-1 (free base)   58045-23-1 (HCl)   85721-05-7 (acetate)   64053-00-5 (decanoate),  

Synonym: Zuclopenthixol dihydrochloride; Zuclopenthixol HCl; alpha-Clopenthixol; Cisordinol; Clopenthixol; Zuclopenthixol; Cisordinol; cis-Clopenthixol; Clopixol;

IUPAC/Chemical Name: 2-[4-[(3Z)-3-(2-Chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol dihydrochloride


InChi Code: InChI=1S/C22H25ClN2OS.2ClH/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26;;/h1-2,4-8,16,26H,3,9-15H2;2*1H/b18-5-;;

SMILES Code: ClC1=CC(/C2=C\CCN3CCN(CCO)CC3)=C(SC4=C2C=CC=C4)C=C1.[H]Cl.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 473.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message

Sent On: Mon Oct 19 09:29:06 2020

Search: Zuclopenthixol [title]

20 selected items

PubMed Results
Items 1-20 of 20 (Display the 20 citations in PubMed)

1: Tveito M, Smith RL, Molden E, Høiseth G. Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients. Eur J Clin Pharmacol. 2020 Sep 30. doi: 10.1007/s00228-020-03002-y. Epub ahead of print. PMID: 33000414.

2: Herath U, Thomas N, Krishna A, Pantelis C. Electroencephalography identifies encephalopathy associated with adjunctive lithium and zuclopenthixol. Aust N Z J Psychiatry. 2019 Aug;53(8):814-815. doi: 10.1177/0004867418823277. Epub 2019 Jan 17. PMID: 30654623.

3: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Zuclopenthixol. 2018 Dec 3. PMID: 30000827.

4: Bryan EJ, Purcell MA, Kumar A. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database Syst Rev. 2017 Nov 16;11(11):CD005474. doi: 10.1002/14651858.CD005474.pub2. PMID: 29144549; PMCID: PMC6486001.

5: Allibe N, Kintz P, Faure A, Paysant F, Michard-Lenoir AP, Stanke-Labesque F, Scolan V, Eysseric-Guerin H. Interest of Single Hair Analysis to Document Drug Exposure: Literature Review and a Case Report Involving Zuclopenthixol. Curr Pharm Des. 2017;23(36):5502-5510. doi: 10.2174/1381612823666170622100443. PMID: 28641534.

6: Tibrewal P, Bastiampillai T, Dhillon R, Cheng R, Fonseka HT. Use of zuclopenthixol in the treatment of aggression in Huntington's disease. Asian J Psychiatr. 2017 Apr;26:152-153. doi: 10.1016/j.ajp.2017.01.011. Epub 2017 Jan 19. PMID: 28483083.

7: Patteet L, Haufroid V, Maudens K, Sabbe B, Morrens M, Neels H. Erratum to: Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2017 Jan;73(1):127. doi: 10.1007/s00228-016-2144-8. Erratum for: Eur J Clin Pharmacol. 2016 Feb;72 (2):175-84. PMID: 27738718.


9: Cordiner M, Shajahan P, McAvoy S, Bashir M, Taylor M. Effectiveness of long- acting antipsychotics in clinical practice: 2. Effects of antipsychotic polypharmacy on risperidone long-acting injection and zuclopenthixol decanoate. Ther Adv Psychopharmacol. 2016 Apr;6(2):66-76. doi: 10.1177/2045125315623584. Epub 2016 Jan 6. PMID: 27141289; PMCID: PMC4837966.

10: Cordiner M, Shajahan P, McAvoy S, Bashir M, Taylor M. Effectiveness of long- acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoate. Ther Adv Psychopharmacol. 2016 Feb;6(1):22-32. doi: 10.1177/2045125315623168. PMID: 26913175; PMCID: PMC4749742.

11: Lacey M, Jayaram MB. Zuclopenthixol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2015 Dec 1;(12):CD010598. doi: 10.1002/14651858.CD010598.pub2. PMID: 26624987.

12: Lisbeth P, Vincent H, Kristof M, Bernard S, Manuel M, Hugo N. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2016 Feb;72(2):175-84. doi: 10.1007/s00228-015-1965-1. Epub 2015 Oct 30. Erratum in: Eur J Clin Pharmacol. 2016 Oct 13;: PMID: 26514968.

13: Hässler F, Dück A, Jung M, Reis O. Treatment of aggressive behavior problems in boys with intellectual disabilities using zuclopenthixol. J Child Adolesc Psychopharmacol. 2014 Dec;24(10):579-81. doi: 10.1089/cap.2014.0066. PMID: 25514543.

14: Wichowicz HM, Wilkowska A, Banecka-Majkutewicz Z, Kummer Ł, Konarzewska J, Raczak A. Mineralizacja jader podstawy jako domniemana przyczyna złej tolerancji zuklopentyksolu u chorej z wieloletnia nieleczona schizofrenia paranoidalna [Mineralization of the basal ganglia as the supposed cause of poor tolerance of zuclopenthixol in a patient with long-term untreated paranoid schizophrenia]. Psychiatr Pol. 2013 Jul-Aug;47(4):599-607. Polish. PMID: 24946467.

15: Lertxundi U, Hernandez R, Albeniz JM, Echaburu SD, Ruiz B, García MG, Aguirre C. Possible interaction between letrozole and long-acting injectable zuclopenthixol. Nord J Psychiatry. 2015 Jan;69(1):79-80. doi: 10.3109/08039488.2014.915341. Epub 2014 May 16. PMID: 24831298.

16: Schwarz V, Reis O, Glaser T, Thome J, Hiemke C, Haessler F. Therapeutic drug monitoring of zuclopenthixol in a double-blind placebo-controlled discontinuation study in adults with intellectual disabilities and aggressive behaviour. Pharmacopsychiatry. 2014 Jan;47(1):29-32. doi: 10.1055/s-0033-1361115. Epub 2013 Dec 4. PMID: 24307207.

17: Rej S, Desautels R. Experience with intramuscular zuclopenthixol and medroxyprogesterone acetate in the treatment of agitation and aggression in Huntington's disease. J Neuropsychiatry Clin Neurosci. 2013 Summer;25(3):E33-4. doi: 10.1176/appi.neuropsych.12070164. PMID: 24026736.

18: Adami C, Wenker C, Hoby S, Morath U, Bergadano A. Anaesthesia with medetomidine-ketamine-isoflurane with and without midazolam, in eight captive chimpanzees (Pan troglodytes) premedicated with oral zuclopenthixol. Schweiz Arch Tierheilkd. 2013 Aug;155(8):471-6. doi: 10.1024/0036-7281/a000493. PMID: 23919974.

19: Janjić V, Milovanović DR, Zecević DR, Loncar D, Laban O, Stepanović M, Varjaric M, Obradović S, Dejanović SD, Janković S. Zuclopenthixol decanoate in pregnancy: successful outcomes in two consecutive offsprings of the same mother. Vojnosanit Pregl. 2013 May;70(5):526-9. doi: 10.2298/vsp120208005j. PMID: 23789295.

20: Menager C, Boimond N, Cheron G. Intoxication au zuclopenthicol benzoate : mise en évidence par chromatographie [Zuclopenthixol benzoate poisoning in a child: evidence from chromatography]. Arch Pediatr. 2013 Mar;20(3):286-8. French. doi: 10.1016/j.arcped.2012.12.009. Epub 2013 Feb 8. PMID: 23465463.